Effects of Combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines

Anti-Cancer Drugs

Volumn 11, Issue 5, 2000, Pages 385-392

  Nabha, Sanaa M ^a   Wall, Nathan R ^a   Mohammad, Ramzi M ^a   Pettit, George R ^b   Al Katib, Ayad M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

B cell lines; Cell cycle; Combretastatin A 4; Growth inhibition

Indexed keywords

ANTILEUKEMIC AGENT; COMBRETASTATIN A4;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL DEATH; CELL GROWTH; CELL STRUCTURE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOID CELL; MITOSIS; PRIORITY JOURNAL;

ANNEXIN A5; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL DIVISION; DNA, NEOPLASM; FLOW CYTOMETRY; HUMANS; LYMPHOMA, B-CELL; MITOSIS; PRODRUGS; STILBENES; TUMOR CELLS, CULTURED;

EID: 0033941680     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200006000-00009     Document Type: Article

References (27)

1. 1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J Clin 2000; 50: 7-33.
2. 2. Horning SJ, Shipp MA, Harris NL. A lymphoma medley: targeted therapy, dose intensification, and differential diagnosis. In: McArthur JR, Schechter G, Shrier SL, eds. American Society of Hematology education program book. American Society of Hematology 1998: 89-111.
3. 3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1998; 48: 6-29.
4. 4. Rubnitz JE, Look AT. Molecular genetics of childhood leukemias. J Pediatr Hematol Oncol 1998; 20: 1-11.
5. 5. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A4. Experientia 1989; 45: 205-11.
6. 6. Woods JA, Hadfield JA Pettit GR, Fox BW, McGown AT. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 1995; 71: 705-11.
7. 7. Hill BT, Whelan RDH. Comparative cell killing and kinetic effects of vincristine or vindesine in mammalian cell lines. J Natl Cancer Inst 1981; 67: 437-43.
8. 8. Jackson DV, Bender RA. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Res 1979; 39: 4346-9.
9. 9. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991; 51: 2212-22.
10. 10. Door RT, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR. Antitumor activity of combretastatin A-4 phosphate, a natural product tubulin inhibitor. Invest New Drugs 1996; 14: 131-7.
11. 11. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 1829-34.
12. 12. Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li L-Y, Smulson ME. Induction of apoptosis in proliferating human endothelial cells by the tumor specific antiangiogenesis agent combretastatin A-4. Cancer Res 1998; 58: 4510-4.
13. 13. Lock RB, Galperina OV, Feldhoff RC, Rhodes LJ. Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in Hela cells. Cancer Res 1994; 54: 4933-9.
14. 14. Koziner B, Stavnezer J, Al-Katib A. Surface immunoglobin light-chain expression by the 'common' ALL cell line REH. Clin Immunol Immunopathol 1985; 37: 135-41.
15. 15. Mohammad RM, Mohamed AN, Hamdan MY, et al. Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia 1996; 10: 130-7.
16. 16. Al-Katib AM, Smith MR, Kamanda WS, et al. Bryostatin-1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 1998; 4: 1305-14.
17. 17. AL-Katib A, Mohammad RM, Hamdan M, Mohamed A, Dan M, Smith M. Propagation of Waldenstrom's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. Blood 1993; 81: 3034-42.
18. 18. Van England M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998; 31: 1-9.
19. 19. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents. Br J Cancer 1996; 74: S87-8.
20. 20. Chaplin DJ, Pettit GR, Hill SA. Antivascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999; 19 (1A): 189-95.
21. 21. McGown AT, Fox BW. Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines. Cancer Chemother Pharmacol 1990; 26: 79-81.
22. 22. Ianzini F, Mackey MA. Spontaneous premature chromosome condensation and mitotic catastrophe following irradiation of Hela S3 cells. Int J Radiat Biol 1997; 72: 409-21.
23. 23. Ianzini F, Mackey MA. Delayed DNA damage associated with mitotic catastrophe following X-irradiation of Hela S3 cells. Mutagenesis 1998; 13: 337-44.
24. 24. Lock RB, Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 1996; 56: 4006-12.
25. 25. Hill SA, Williams KB, Denekamp J. Vascular collapse after flavone acetic acid: a possible mechanism of its antitumour action. Eur J Cancer Clin Oncol 1989; 25: 1419-24.
26. 26. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 1993; 29A: 1320-4.
27. 27. O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amin-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 1999; 5: 181-7.